Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors
Sponsor: BeiGene
A PHASE1 clinical study on Solid Tumors, this trial is completed. The trial is conducted by BeiGene and has accumulated 14 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE1
-
Nov 2024 — Jan 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
▶ Show 9 earlier versions
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Dec 2019 — Apr 2020 [monthly]
Completed PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Completed PHASE1
-
Oct 2019 — Nov 2019 [monthly]
Completed PHASE1
-
Aug 2019 — Oct 2019 [monthly]
Completed PHASE1
-
Jan 2019 — Aug 2019 [monthly]
Completed PHASE1
-
Aug 2018 — Jan 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BeiGene
For direct contact, visit the study record on ClinicalTrials.gov .